Stefan Sillau
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 23 | 2026 | 600 | 2.190 |
Why?
| | Epilepsies, Partial | 7 | 2026 | 61 | 1.400 |
Why?
| | Seizures | 12 | 2026 | 460 | 1.140 |
Why?
| | Alzheimer Disease | 6 | 2025 | 619 | 1.100 |
Why?
| | Multiple Sclerosis | 9 | 2025 | 484 | 1.060 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2025 | 161 | 0.910 |
Why?
| | Drug Resistant Epilepsy | 5 | 2026 | 124 | 0.860 |
Why?
| | Palliative Care | 13 | 2026 | 996 | 0.850 |
Why?
| | Quality of Life | 18 | 2026 | 3166 | 0.760 |
Why?
| | Epilepsy | 5 | 2024 | 375 | 0.630 |
Why?
| | Caregivers | 9 | 2024 | 1047 | 0.570 |
Why?
| | Middle Aged | 56 | 2026 | 35762 | 0.520 |
Why?
| | Neurons | 1 | 2025 | 1640 | 0.490 |
Why?
| | Humans | 114 | 2026 | 144261 | 0.480 |
Why?
| | Cognition | 8 | 2025 | 1258 | 0.480 |
Why?
| | Aged | 44 | 2026 | 25850 | 0.480 |
Why?
| | Natalizumab | 4 | 2021 | 41 | 0.480 |
Why?
| | Stroke | 5 | 2026 | 1254 | 0.470 |
Why?
| | Aging | 2 | 2025 | 1964 | 0.450 |
Why?
| | Male | 72 | 2026 | 72035 | 0.450 |
Why?
| | Parkinsonian Disorders | 3 | 2020 | 43 | 0.440 |
Why?
| | Healthcare Disparities | 4 | 2026 | 725 | 0.440 |
Why?
| | Fingolimod Hydrochloride | 3 | 2020 | 39 | 0.440 |
Why?
| | Female | 72 | 2026 | 77976 | 0.420 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 451 | 0.420 |
Why?
| | Anticonvulsants | 3 | 2026 | 234 | 0.410 |
Why?
| | Aged, 80 and over | 20 | 2026 | 8243 | 0.410 |
Why?
| | Retrospective Studies | 36 | 2026 | 17009 | 0.410 |
Why?
| | Young Adult | 26 | 2026 | 13990 | 0.400 |
Why?
| | Adult | 44 | 2026 | 40262 | 0.400 |
Why?
| | Immunologic Factors | 3 | 2020 | 255 | 0.370 |
Why?
| | Psychotherapy, Group | 2 | 2026 | 80 | 0.370 |
Why?
| | Atherosclerosis | 4 | 2019 | 404 | 0.360 |
Why?
| | Cognition Disorders | 3 | 2024 | 537 | 0.350 |
Why?
| | Cannabidiol | 2 | 2024 | 136 | 0.340 |
Why?
| | Charcot-Marie-Tooth Disease | 2 | 2022 | 21 | 0.340 |
Why?
| | Diabetic Neuropathies | 2 | 2023 | 97 | 0.340 |
Why?
| | Neuropsychological Tests | 4 | 2025 | 1129 | 0.330 |
Why?
| | Ambulatory Care | 3 | 2020 | 597 | 0.330 |
Why?
| | Chagas Disease | 2 | 2021 | 42 | 0.330 |
Why?
| | Music Therapy | 2 | 2021 | 22 | 0.320 |
Why?
| | Sinusitis | 3 | 2021 | 228 | 0.320 |
Why?
| | Rural Health Services | 2 | 2025 | 141 | 0.300 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 0.300 |
Why?
| | Torticollis | 2 | 2019 | 17 | 0.290 |
Why?
| | Meningitis, Cryptococcal | 2 | 2019 | 34 | 0.280 |
Why?
| | Rituximab | 2 | 2020 | 209 | 0.280 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 2 | 2020 | 82 | 0.280 |
Why?
| | Emergency Medical Services | 2 | 2026 | 696 | 0.280 |
Why?
| | Dystonic Disorders | 2 | 2019 | 27 | 0.280 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 77 | 0.270 |
Why?
| | Adolescent | 21 | 2026 | 22281 | 0.270 |
Why?
| | Cardiomyopathies | 2 | 2021 | 337 | 0.260 |
Why?
| | Medical Staff, Hospital | 2 | 2021 | 80 | 0.250 |
Why?
| | Spirituality | 4 | 2021 | 88 | 0.250 |
Why?
| | Treatment Outcome | 17 | 2026 | 11643 | 0.250 |
Why?
| | Myelitis | 2 | 2018 | 107 | 0.250 |
Why?
| | Cannabis | 2 | 2024 | 509 | 0.240 |
Why?
| | Chlorophenols | 1 | 2026 | 16 | 0.240 |
Why?
| | Dissociative Disorders | 1 | 2026 | 30 | 0.240 |
Why?
| | Colorado | 14 | 2025 | 4562 | 0.240 |
Why?
| | Tetrazoles | 1 | 2026 | 50 | 0.240 |
Why?
| | Carbamates | 1 | 2026 | 52 | 0.230 |
Why?
| | Suburban Health Services | 1 | 2025 | 4 | 0.230 |
Why?
| | Sepsis | 2 | 2022 | 640 | 0.230 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.230 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 123 | 0.220 |
Why?
| | Neurosurgical Procedures | 2 | 2017 | 202 | 0.220 |
Why?
| | Urban Health Services | 1 | 2025 | 70 | 0.220 |
Why?
| | Rural Health | 1 | 2025 | 87 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 11 | 2024 | 3857 | 0.220 |
Why?
| | Stiff-Person Syndrome | 1 | 2024 | 13 | 0.220 |
Why?
| | Prevalence | 9 | 2024 | 2815 | 0.220 |
Why?
| | Candidemia | 1 | 2024 | 15 | 0.220 |
Why?
| | Arterial Occlusive Diseases | 1 | 2025 | 90 | 0.220 |
Why?
| | Thrombectomy | 1 | 2025 | 77 | 0.220 |
Why?
| | Candida | 1 | 2024 | 44 | 0.220 |
Why?
| | Vulnerable Populations | 1 | 2026 | 173 | 0.220 |
Why?
| | Ischemic Attack, Transient | 1 | 2025 | 71 | 0.210 |
Why?
| | Brain | 6 | 2023 | 2930 | 0.210 |
Why?
| | Nasal Polyps | 2 | 2016 | 59 | 0.210 |
Why?
| | Adaptation, Psychological | 5 | 2020 | 706 | 0.210 |
Why?
| | Aquaporin 4 | 1 | 2024 | 98 | 0.210 |
Why?
| | Cerebral Amyloid Angiopathy | 1 | 2024 | 9 | 0.210 |
Why?
| | Dronabinol | 2 | 2024 | 247 | 0.210 |
Why?
| | Community Health Services | 1 | 2026 | 232 | 0.210 |
Why?
| | Cell Death | 1 | 2025 | 383 | 0.210 |
Why?
| | Child Abuse | 2 | 2022 | 550 | 0.210 |
Why?
| | Brain Ischemia | 2 | 2025 | 358 | 0.200 |
Why?
| | Patient Reported Outcome Measures | 2 | 2026 | 487 | 0.200 |
Why?
| | Dimethyl Fumarate | 2 | 2020 | 12 | 0.200 |
Why?
| | Telemedicine | 2 | 2024 | 940 | 0.200 |
Why?
| | Cost of Illness | 3 | 2021 | 319 | 0.200 |
Why?
| | Risk Assessment | 7 | 2026 | 3637 | 0.200 |
Why?
| | Child | 16 | 2025 | 22537 | 0.200 |
Why?
| | Self Report | 4 | 2025 | 863 | 0.190 |
Why?
| | Fatigue | 1 | 2025 | 361 | 0.190 |
Why?
| | Patient Discharge | 3 | 2026 | 977 | 0.190 |
Why?
| | Neuromyelitis Optica | 1 | 2024 | 137 | 0.190 |
Why?
| | Cohort Studies | 10 | 2026 | 5935 | 0.190 |
Why?
| | Inpatients | 3 | 2021 | 542 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2026 | 321 | 0.190 |
Why?
| | Patient Care Team | 3 | 2019 | 686 | 0.190 |
Why?
| | Quality Indicators, Health Care | 1 | 2025 | 335 | 0.190 |
Why?
| | Severity of Illness Index | 8 | 2020 | 2917 | 0.180 |
Why?
| | Migraine Disorders | 1 | 2024 | 112 | 0.180 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1091 | 0.180 |
Why?
| | Apolipoprotein E4 | 1 | 2022 | 41 | 0.180 |
Why?
| | Conversion Disorder | 1 | 2022 | 10 | 0.180 |
Why?
| | Vagus Nerve Stimulation | 1 | 2022 | 29 | 0.180 |
Why?
| | Frontotemporal Dementia | 1 | 2022 | 57 | 0.180 |
Why?
| | Biomarkers | 4 | 2025 | 4254 | 0.170 |
Why?
| | Memory Consolidation | 1 | 2021 | 14 | 0.170 |
Why?
| | Chagas Cardiomyopathy | 1 | 2021 | 27 | 0.170 |
Why?
| | Motor Disorders | 1 | 2021 | 17 | 0.170 |
Why?
| | Atrophy | 4 | 2024 | 200 | 0.170 |
Why?
| | Dermatitis, Seborrheic | 1 | 2020 | 5 | 0.170 |
Why?
| | Interleukin-6 | 1 | 2025 | 780 | 0.170 |
Why?
| | Risk Factors | 12 | 2026 | 10699 | 0.170 |
Why?
| | Guideline Adherence | 1 | 2025 | 586 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1217 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2022 | 174 | 0.160 |
Why?
| | Basal Ganglia Diseases | 1 | 2020 | 9 | 0.160 |
Why?
| | Vitamin D | 2 | 2015 | 399 | 0.160 |
Why?
| | Endovascular Procedures | 1 | 2025 | 384 | 0.160 |
Why?
| | Incidence | 6 | 2024 | 2870 | 0.160 |
Why?
| | Sleep | 3 | 2021 | 901 | 0.160 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 28 | 0.160 |
Why?
| | Cross-Sectional Studies | 10 | 2021 | 5813 | 0.160 |
Why?
| | Disease Progression | 4 | 2022 | 2840 | 0.160 |
Why?
| | Sphenoid Bone | 2 | 2016 | 15 | 0.160 |
Why?
| | Cytokines | 3 | 2022 | 2061 | 0.160 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2022 | 107 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.160 |
Why?
| | Time Factors | 8 | 2026 | 7155 | 0.150 |
Why?
| | Neurovascular Coupling | 1 | 2019 | 9 | 0.150 |
Why?
| | Attitude of Health Personnel | 2 | 2021 | 1182 | 0.150 |
Why?
| | Terminal Care | 1 | 2023 | 279 | 0.150 |
Why?
| | Shock, Septic | 1 | 2021 | 215 | 0.150 |
Why?
| | Behavioral Symptoms | 1 | 2019 | 43 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2016 | 222 | 0.150 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 18 | 0.150 |
Why?
| | Critical Care Outcomes | 1 | 2018 | 11 | 0.150 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2516 | 0.140 |
Why?
| | Electronic Health Records | 2 | 2021 | 1169 | 0.140 |
Why?
| | Blepharospasm | 1 | 2018 | 7 | 0.140 |
Why?
| | Streptococcal Infections | 1 | 2021 | 168 | 0.140 |
Why?
| | Restless Legs Syndrome | 1 | 2018 | 20 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 37 | 0.140 |
Why?
| | Depression | 3 | 2026 | 1533 | 0.140 |
Why?
| | Cannabinoids | 1 | 2020 | 182 | 0.140 |
Why?
| | Fluoxetine | 1 | 2018 | 54 | 0.140 |
Why?
| | Proxy | 1 | 2018 | 34 | 0.140 |
Why?
| | Psychometrics | 2 | 2019 | 730 | 0.140 |
Why?
| | Aftercare | 1 | 2020 | 220 | 0.140 |
Why?
| | United States | 11 | 2026 | 15876 | 0.140 |
Why?
| | Basal Ganglia | 1 | 2018 | 57 | 0.140 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.140 |
Why?
| | Electroencephalography | 4 | 2022 | 532 | 0.130 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2018 | 78 | 0.130 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4556 | 0.130 |
Why?
| | Neurology | 1 | 2019 | 110 | 0.130 |
Why?
| | Nutrition Surveys | 1 | 2019 | 281 | 0.130 |
Why?
| | Transcranial Magnetic Stimulation | 1 | 2017 | 64 | 0.130 |
Why?
| | Child, Preschool | 5 | 2025 | 11774 | 0.130 |
Why?
| | Subthalamic Nucleus | 1 | 2018 | 83 | 0.130 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2017 | 46 | 0.130 |
Why?
| | Cranial Nerve Diseases | 1 | 2017 | 43 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2019 | 846 | 0.130 |
Why?
| | Apoptosis | 1 | 2025 | 2430 | 0.130 |
Why?
| | Rats | 1 | 2025 | 5592 | 0.130 |
Why?
| | Down Syndrome | 2 | 2022 | 534 | 0.130 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 264 | 0.130 |
Why?
| | Interprofessional Relations | 1 | 2019 | 280 | 0.120 |
Why?
| | Movement Disorders | 1 | 2017 | 69 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 108 | 0.120 |
Why?
| | Autism Spectrum Disorder | 1 | 2022 | 412 | 0.120 |
Why?
| | Immunoglobulin G | 1 | 2021 | 893 | 0.120 |
Why?
| | Medical Marijuana | 1 | 2018 | 123 | 0.120 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2016 | 8 | 0.120 |
Why?
| | Orbital Diseases | 1 | 2016 | 35 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2018 | 145 | 0.120 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5389 | 0.120 |
Why?
| | Cerebellum | 1 | 2018 | 223 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2020 | 582 | 0.120 |
Why?
| | Skull Base Neoplasms | 1 | 2016 | 29 | 0.120 |
Why?
| | Meningioma | 1 | 2016 | 86 | 0.120 |
Why?
| | Meningeal Neoplasms | 1 | 2016 | 93 | 0.120 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2016 | 141 | 0.120 |
Why?
| | Craniocerebral Trauma | 1 | 2017 | 176 | 0.120 |
Why?
| | Family | 2 | 2024 | 679 | 0.110 |
Why?
| | Regression Analysis | 2 | 2018 | 998 | 0.110 |
Why?
| | Dementia | 1 | 2019 | 302 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2018 | 250 | 0.110 |
Why?
| | Deep Brain Stimulation | 1 | 2018 | 212 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1982 | 0.110 |
Why?
| | Motor Activity | 1 | 2019 | 720 | 0.110 |
Why?
| | Data Collection | 2 | 2022 | 633 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2022 | 2926 | 0.110 |
Why?
| | Craniofacial Abnormalities | 1 | 2015 | 76 | 0.110 |
Why?
| | Hemodynamics | 1 | 2019 | 1119 | 0.110 |
Why?
| | Neonatal Screening | 1 | 2016 | 178 | 0.100 |
Why?
| | Patient Readmission | 1 | 2020 | 756 | 0.100 |
Why?
| | Physicians | 1 | 2023 | 938 | 0.100 |
Why?
| | Ureteroscopy | 1 | 2014 | 16 | 0.100 |
Why?
| | Rhinitis | 1 | 2016 | 171 | 0.100 |
Why?
| | Burnout, Professional | 1 | 2021 | 484 | 0.100 |
Why?
| | Vitamin D Deficiency | 2 | 2015 | 185 | 0.100 |
Why?
| | Urolithiasis | 1 | 2014 | 11 | 0.100 |
Why?
| | Depressive Disorder | 1 | 2017 | 374 | 0.100 |
Why?
| | Aspirin | 2 | 2016 | 399 | 0.100 |
Why?
| | Behavioral Medicine | 1 | 2014 | 40 | 0.100 |
Why?
| | Anxiety Disorders | 1 | 2017 | 368 | 0.100 |
Why?
| | Patient-Centered Care | 1 | 2019 | 540 | 0.100 |
Why?
| | Eosinophilia | 1 | 2016 | 221 | 0.100 |
Why?
| | Extremities | 1 | 2014 | 140 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 557 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2024 | 1322 | 0.100 |
Why?
| | Nervous System Diseases | 1 | 2016 | 282 | 0.100 |
Why?
| | Retinopathy of Prematurity | 1 | 2016 | 179 | 0.100 |
Why?
| | Chronic Disease | 2 | 2016 | 1812 | 0.100 |
Why?
| | Internet | 2 | 2024 | 698 | 0.100 |
Why?
| | Airway Obstruction | 1 | 2015 | 162 | 0.100 |
Why?
| | Pulmonary Ventilation | 1 | 2013 | 83 | 0.100 |
Why?
| | Demography | 1 | 2014 | 284 | 0.100 |
Why?
| | Length of Stay | 2 | 2025 | 1335 | 0.100 |
Why?
| | Double-Blind Method | 3 | 2024 | 2025 | 0.100 |
Why?
| | Tonsillectomy | 1 | 2015 | 105 | 0.100 |
Why?
| | Primary Prevention | 1 | 2015 | 219 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 1137 | 0.090 |
Why?
| | Birth Weight | 1 | 2016 | 522 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2018 | 767 | 0.090 |
Why?
| | Refugees | 1 | 2014 | 81 | 0.090 |
Why?
| | Mental Disorders | 1 | 2021 | 1138 | 0.090 |
Why?
| | Prognosis | 4 | 2023 | 4278 | 0.090 |
Why?
| | Calcinosis | 1 | 2014 | 233 | 0.090 |
Why?
| | Coronary Vessels | 1 | 2014 | 251 | 0.090 |
Why?
| | Movement | 1 | 2014 | 293 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 4 | 2016 | 2730 | 0.090 |
Why?
| | Teaching Rounds | 1 | 2013 | 73 | 0.090 |
Why?
| | Weight Gain | 1 | 2016 | 556 | 0.090 |
Why?
| | Coronary Disease | 1 | 2014 | 381 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 1983 | 0.090 |
Why?
| | Curriculum | 1 | 2019 | 1057 | 0.090 |
Why?
| | Prospective Studies | 6 | 2025 | 7970 | 0.090 |
Why?
| | Anxiety | 3 | 2026 | 1104 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 434 | 0.080 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 297 | 0.080 |
Why?
| | Interpersonal Relations | 1 | 2014 | 399 | 0.080 |
Why?
| | Tissue Donors | 1 | 2014 | 424 | 0.080 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 299 | 0.080 |
Why?
| | Environmental Monitoring | 1 | 2013 | 377 | 0.080 |
Why?
| | Reproducibility of Results | 4 | 2022 | 3403 | 0.080 |
Why?
| | Amyloid beta-Peptides | 2 | 2023 | 240 | 0.080 |
Why?
| | Internal Medicine | 1 | 2013 | 280 | 0.080 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 132 | 0.080 |
Why?
| | Age of Onset | 2 | 2023 | 536 | 0.080 |
Why?
| | Tissue and Organ Procurement | 1 | 2014 | 346 | 0.080 |
Why?
| | Surveys and Questionnaires | 6 | 2019 | 6021 | 0.080 |
Why?
| | Polysomnography | 3 | 2015 | 234 | 0.080 |
Why?
| | Obesity | 2 | 2021 | 3057 | 0.080 |
Why?
| | Cross Infection | 1 | 2012 | 262 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2023 | 3592 | 0.070 |
Why?
| | Models, Statistical | 1 | 2013 | 677 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3157 | 0.070 |
Why?
| | Health Status | 1 | 2014 | 833 | 0.070 |
Why?
| | Calcium | 1 | 2014 | 1182 | 0.070 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 741 | 0.070 |
Why?
| | Quality of Health Care | 1 | 2013 | 688 | 0.070 |
Why?
| | Sex Factors | 2 | 2026 | 2096 | 0.070 |
Why?
| | Internship and Residency | 1 | 2019 | 1255 | 0.070 |
Why?
| | Asthma | 3 | 2016 | 1767 | 0.070 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1318 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2017 | 2916 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1759 | 0.070 |
Why?
| | Urban Population | 2 | 2025 | 490 | 0.070 |
Why?
| | Cardiac Surgical Procedures | 1 | 2013 | 609 | 0.060 |
Why?
| | Patient Participation | 2 | 2022 | 429 | 0.060 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1792 | 0.060 |
Why?
| | Lung Diseases | 1 | 2013 | 787 | 0.060 |
Why?
| | Recurrence | 2 | 2020 | 1134 | 0.060 |
Why?
| | Intensive Care Units | 1 | 2012 | 916 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1254 | 0.060 |
Why?
| | Animals | 2 | 2025 | 38030 | 0.060 |
Why?
| | Influenza, Human | 1 | 2011 | 615 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1382 | 0.060 |
Why?
| | Critical Illness | 1 | 2012 | 889 | 0.060 |
Why?
| | Heart Defects, Congenital | 1 | 2013 | 913 | 0.060 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.060 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1409 | 0.060 |
Why?
| | Feasibility Studies | 2 | 2019 | 1087 | 0.050 |
Why?
| | Neurologists | 1 | 2024 | 22 | 0.050 |
Why?
| | Research Design | 2 | 2021 | 1129 | 0.050 |
Why?
| | Syncope | 1 | 2024 | 55 | 0.050 |
Why?
| | Amyloidogenic Proteins | 1 | 2023 | 16 | 0.050 |
Why?
| | Comorbidity | 2 | 2021 | 1646 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 25 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1705 | 0.050 |
Why?
| | American Heart Association | 1 | 2025 | 348 | 0.050 |
Why?
| | Sleep Wake Disorders | 2 | 2019 | 301 | 0.050 |
Why?
| | Primary Health Care | 1 | 2014 | 1710 | 0.050 |
Why?
| | Pandemics | 2 | 2022 | 1682 | 0.050 |
Why?
| | Death | 1 | 2024 | 130 | 0.050 |
Why?
| | Tremor | 1 | 2024 | 98 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2025 | 240 | 0.050 |
Why?
| | Cerebral Hemorrhage | 1 | 2024 | 120 | 0.050 |
Why?
| | Vaccination | 1 | 2011 | 1422 | 0.050 |
Why?
| | Myelin P0 Protein | 1 | 2022 | 7 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1559 | 0.050 |
Why?
| | Imipramine | 1 | 2022 | 11 | 0.050 |
Why?
| | Organ Size | 1 | 2023 | 462 | 0.050 |
Why?
| | Pain | 2 | 2018 | 777 | 0.050 |
Why?
| | tau Proteins | 1 | 2023 | 114 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 964 | 0.050 |
Why?
| | Facial Expression | 1 | 2022 | 74 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 423 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1980 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 214 | 0.040 |
Why?
| | Polymerization | 1 | 2022 | 130 | 0.040 |
Why?
| | Vagus Nerve | 1 | 2022 | 91 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 177 | 0.040 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 8 | 0.040 |
Why?
| | Catalysis | 1 | 2022 | 322 | 0.040 |
Why?
| | Oncology Service, Hospital | 1 | 2021 | 15 | 0.040 |
Why?
| | Interneurons | 1 | 2022 | 128 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2111 | 0.040 |
Why?
| | Immune System | 1 | 2022 | 179 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2877 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 172 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 176 | 0.040 |
Why?
| | Rural Population | 1 | 2025 | 648 | 0.040 |
Why?
| | Outpatients | 1 | 2024 | 439 | 0.040 |
Why?
| | Serine | 1 | 2021 | 145 | 0.040 |
Why?
| | Lung | 1 | 2013 | 4108 | 0.040 |
Why?
| | Medical Informatics | 1 | 2021 | 97 | 0.040 |
Why?
| | Reaction Time | 1 | 2022 | 438 | 0.040 |
Why?
| | Longevity | 1 | 2021 | 173 | 0.040 |
Why?
| | Astrocytes | 1 | 2022 | 222 | 0.040 |
Why?
| | Efficiency, Organizational | 1 | 2021 | 139 | 0.040 |
Why?
| | Electrodes, Implanted | 1 | 2020 | 115 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 289 | 0.040 |
Why?
| | Age Distribution | 1 | 2020 | 397 | 0.040 |
Why?
| | Multiple System Atrophy | 1 | 2019 | 8 | 0.040 |
Why?
| | Sex Distribution | 1 | 2020 | 380 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2023 | 698 | 0.040 |
Why?
| | Supranuclear Palsy, Progressive | 1 | 2019 | 18 | 0.040 |
Why?
| | Income | 1 | 2020 | 199 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2022 | 281 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 672 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 42 | 0.040 |
Why?
| | Music | 1 | 2019 | 47 | 0.040 |
Why?
| | Lewy Body Disease | 1 | 2019 | 33 | 0.040 |
Why?
| | Infant | 3 | 2018 | 10022 | 0.040 |
Why?
| | Logistic Models | 2 | 2014 | 2104 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 137 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 87 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 132 | 0.030 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 84 | 0.030 |
Why?
| | Stroke Volume | 1 | 2021 | 648 | 0.030 |
Why?
| | Gait | 1 | 2021 | 313 | 0.030 |
Why?
| | Phosphorus | 1 | 2018 | 99 | 0.030 |
Why?
| | Carnitine | 1 | 2018 | 90 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 538 | 0.030 |
Why?
| | Muscle Spasticity | 1 | 2018 | 63 | 0.030 |
Why?
| | Administration, Oral | 1 | 2020 | 847 | 0.030 |
Why?
| | Health Services | 1 | 2019 | 114 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 73 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 876 | 0.030 |
Why?
| | Gadolinium | 1 | 2018 | 84 | 0.030 |
Why?
| | Neural Pathways | 1 | 2019 | 311 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 169 | 0.030 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 360 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 576 | 0.030 |
Why?
| | Registries | 1 | 2026 | 2382 | 0.030 |
Why?
| | Neural Conduction | 1 | 2017 | 92 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2019 | 308 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 577 | 0.030 |
Why?
| | Exophthalmos | 1 | 2016 | 17 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 985 | 0.030 |
Why?
| | Temporomandibular Joint | 1 | 2016 | 8 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 612 | 0.030 |
Why?
| | Occipital Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Brain Mapping | 1 | 2019 | 536 | 0.030 |
Why?
| | Neuroimaging | 1 | 2019 | 289 | 0.030 |
Why?
| | Frontal Bone | 1 | 2016 | 18 | 0.030 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 19 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 789 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 965 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 778 | 0.030 |
Why?
| | Temporal Bone | 1 | 2016 | 45 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 155 | 0.030 |
Why?
| | Qualitative Research | 1 | 2024 | 1659 | 0.030 |
Why?
| | Self Efficacy | 1 | 2019 | 411 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2016 | 307 | 0.030 |
Why?
| | Neoplasm, Residual | 1 | 2016 | 139 | 0.030 |
Why?
| | Sleep Stages | 1 | 2015 | 75 | 0.030 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2017 | 537 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2018 | 440 | 0.030 |
Why?
| | Contrast Media | 1 | 2018 | 486 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2019 | 898 | 0.030 |
Why?
| | Electromyography | 1 | 2017 | 415 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 90 | 0.030 |
Why?
| | Thinness | 1 | 2015 | 99 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 145 | 0.030 |
Why?
| | Age Factors | 1 | 2022 | 3313 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2015 | 81 | 0.030 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 97 | 0.030 |
Why?
| | San Francisco | 1 | 2014 | 60 | 0.030 |
Why?
| | Sampling Studies | 1 | 2014 | 99 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1075 | 0.030 |
Why?
| | Sternotomy | 1 | 2013 | 23 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 121 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1264 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2016 | 6424 | 0.020 |
Why?
| | Pilot Projects | 1 | 2019 | 1867 | 0.020 |
Why?
| | Leukotriene E4 | 1 | 2013 | 24 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 119 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2013 | 18 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1072 | 0.020 |
Why?
| | Lithotripsy | 1 | 2014 | 49 | 0.020 |
Why?
| | Thoracotomy | 1 | 2013 | 83 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2013 | 155 | 0.020 |
Why?
| | Linear Models | 1 | 2015 | 850 | 0.020 |
Why?
| | Hospitals, Teaching | 1 | 2013 | 119 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 254 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 153 | 0.020 |
Why?
| | Spirometry | 1 | 2013 | 230 | 0.020 |
Why?
| | Olfaction Disorders | 1 | 2013 | 70 | 0.020 |
Why?
| | Paranasal Sinuses | 1 | 2013 | 81 | 0.020 |
Why?
| | Vital Capacity | 1 | 2013 | 290 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2014 | 322 | 0.020 |
Why?
| | Gestational Age | 1 | 2016 | 975 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2013 | 448 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2014 | 538 | 0.020 |
Why?
| | Paper | 1 | 2011 | 9 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 878 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 768 | 0.020 |
Why?
| | Personnel, Hospital | 1 | 2011 | 31 | 0.020 |
Why?
| | Critical Care | 1 | 2017 | 694 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4085 | 0.020 |
Why?
| | Premature Birth | 1 | 2015 | 380 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 316 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2013 | 233 | 0.020 |
Why?
| | Exercise Test | 1 | 2013 | 634 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2013 | 724 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 347 | 0.020 |
Why?
| | Patient Admission | 1 | 2012 | 218 | 0.020 |
Why?
| | Cause of Death | 1 | 2012 | 464 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1312 | 0.020 |
Why?
| | Recovery of Function | 1 | 2013 | 706 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 1025 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1820 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 1834 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2011 | 529 | 0.020 |
Why?
| | Mice | 1 | 2022 | 18329 | 0.010 |
Why?
|
|
Sillau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|